Dt&C Decides Treasury Share Cancellation and Cash Dividend; Consolidated Operating Loss Continues
Board decided on Jan 21, 2026 to cancel 173,088 treasury shares; completed on Jan 23, reducing outstanding shares to 11,524,933.
Declared cash dividend for FY2025: dividend payable of 1,152.5 million won (approx. 100 won per share).
Separate (parent) Q1 2026: revenue 14.06 billion won (+14.3% YoY), operating profit 1.87 billion won (swing to profit), net income 12.02 billion won (includes 10.28 billion gain from subsidiary disposal).
Consolidated Q1 2026: revenue 28.39 billion won (slight decline YoY), operating loss 1.90 billion won (widened), controlling interest net income 6.18 billion won.
Subsidiary Labti (랩티) was fully disposed on Jan 2, 2026; gain on disposal 8.56 billion won (consolidated) / 10.28 billion (separate).
Medical segment (mainly Dt&C CRO) posted consolidated operating loss of 14.20 billion won, deepening losses.
Convertible bonds and bonds with warrants: parent's 5th series CB 5.85 billion won (conversion price 2,924 won); subsidiaries issued about 20 billion won in new CB/BW in Feb 2026.
Total borrowings (short+long) consolidated 72.68 billion won; debt-to-equity ratio 133.1%.